ERBB2 and breast carcinoma: These diagnostic approaches are crucial for accurately identifying HER2-positive breast cancer patients who may benefit from HER2-targeted therapies such as neratinib, trastuzumab deruxtecan, pertuzumab, and ado-trastuzumab emtansine (T-DM1).